Your browser doesn't support javascript.
loading
After Theranos: Using point-of-care testing to advance measures of health biomarkers in human biology research.
Gildner, Theresa E; Eick, Geeta N; Schneider, Alaina L; Madimenos, Felicia C; Snodgrass, J Josh.
Afiliación
  • Gildner TE; Department of Anthropology, Washington University in St. Louis, St. Louis, Missouri, USA.
  • Eick GN; Department of Anthropology, University of Oregon, Eugene, Oregon, USA.
  • Schneider AL; Department of Anthropology, Washington University in St. Louis, St. Louis, Missouri, USA.
  • Madimenos FC; Department of Anthropology, Queens College (CUNY), Flushing, New York, USA.
  • Snodgrass JJ; Department of Anthropology, University of Oregon, Eugene, Oregon, USA.
Am J Hum Biol ; 34(11): e23689, 2022 11.
Article en En | MEDLINE | ID: mdl-34669210
OBJECTIVES: The rise and fall of the health technology startup Theranos is emblematic of the promise and peril of point-of-care testing (POCT). Instruments that deliver immediate results from minimally invasive samples at the location of collection can provide powerful tools to deliver health data in clinical and public health contexts. Yet, POCT availability is driven largely by market interests, which limits the development of inexpensive tests for diverse health conditions that can be used in resource-limited settings. These constraints, combined with complex regulatory hurdles and substantial ethical challenges, have contributed to the underutilization of POCT in human biology research. METHODS: We evaluate current POCT capabilities and limitations, discuss promising applications for POCT devices in resource-limited settings, and discuss the future of POCT. RESULTS: As evidenced by publication trends, POCT platforms have rapidly advanced in recent years, gaining traction among clinicians and health researchers. We highlight POCT devices of potential interest to population-based researchers and present specific examples of POCT applications in human biology research. CONCLUSIONS: Several barriers can limit POCT applications, including cost, lack of regulatory approval for non-clinical use, requirements for expensive equipment, and the dearth of validation in remote field conditions. Despite these issues, we see immense potential for emerging POCT technology capable of analyzing new sample types and used in conjunction with increasingly common technology (e.g., smart phones). We argue that the fallout from Theranos may ultimately provide an opportunity to advance POCT, leading to more ethical data collection and novel opportunities in human biology research.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Sistemas de Atención de Punto / Pruebas en el Punto de Atención Tipo de estudio: Diagnostic_studies Aspecto: Ethics / Patient_preference Límite: Humans Idioma: En Revista: Am J Hum Biol Asunto de la revista: BIOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Sistemas de Atención de Punto / Pruebas en el Punto de Atención Tipo de estudio: Diagnostic_studies Aspecto: Ethics / Patient_preference Límite: Humans Idioma: En Revista: Am J Hum Biol Asunto de la revista: BIOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos